Abstract: Objective   To investigate the effect of rs10013228 polymorphism of vascular endothelial growth factor receptor 2 （VEGFR2） gene on the prognosis of patients with colorectal cancer after R0 resection. Methods   From January 2010 to December 2015， 154 cases of peripheral blood samples and 93 cases of postoperative cancer tissue specimens were collected from 154 patients with colorectal cancer who underwent R0 resection. Genotyping of VEGFR2 gene rs10013228 locus was performed by Tagman probe PCR genotyping. Real-time quantitative PCR （QPCR） was used to detect the level of VEGFR2 mRNA in tissues. The relationships between the distribution of rs10013228 genotype and clinicopathological parameters （age， sex， tumor location， differentiation， pathological stage and adjuvant chemotherapy） as well as the level of VEGFR2 mRNA were analyzed. The prognosis of different genotypes of rs10013228 was analyzed according to the follow-up data， and the multifactor analysis was carried out by the Cox risk proportion model. Results   Among all 154 patients， there were 95 cases of rs10013228 AA gene type（61.69％）， 51 cases of AG gene type（33.12％） and 8 cases of GG gene type （5.19％） with the minimum allele frequency of 0.22. The distribution of different genotypes was not related to age， sex， tumor location， differentiation， pathological stage and adjuvant chemotherapy （P＞0.05）. The median survival time （OS） of 154 colorectal cancer patients was 4.90 years. Single factor analysis showed that sex and tumor site were not related to OS， but age， degree of differentiation， pathological stage， adjuvant chemotherapy and rs10013228 gene type were related to OS. The median OS of rs10013228 AG/GG gene type was 5.60 years， longer than that of AA type （P＜0.05）. Multivariate analysis showed that age， pathological stage and rs10013228 were independent prognostic factors for colorectal cancer patients. QPCR detection showed that VEGFR2 mRNA level of AA type was higher than that of AG/GG （4.26±1.21 vs. 2.94±0.88）， and the difference was statistically significant （P＜0.05）. Conclusion  The VEGFR2 rs10013228 in colorectal cancer patients is related to the expression of VEGFR2 and the prognosis. Patients carrying the mutant allele of VEGFR2 present a lower expression of VEGFR2 and a better prognosis. It may affect the prognosis by influencing the expression of VEGFR2.

Key words: Colorectal cancer, Vascular endothelial growth factor receptor 2（VEGFR2）, Polymorphism, Prognosis